Group 1 - Sonnet BioTherapeutics Holdings, Inc. announced that its stockholders approved the proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC at a special meeting [1] - The final voting results for the special meeting will be filed in a Form 8-K with the U.S. Securities and Exchange Commission [1] Group 2 - Sonnet BioTherapeutics is an oncology-focused biotechnology company that utilizes a proprietary platform known as FHAB (Fully Human Albumin Binding) for developing biologic drugs [2] - The FHAB technology employs a fully human single chain antibody fragment that binds to human serum albumin for targeted transport to tumor and lymphatic tissues, enhancing the safety and efficacy of immune modulating biologic drugs [2] - FHAB serves as a modular construct for various large molecule therapeutic classes, including cytokines, peptides, antibodies, and vaccines [2]

Core Viewpoint - Sonnet BioTherapeutics Holdings, Inc. has adjourned its special meeting of stockholders to allow additional time for stockholders to vote on the proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC, with over 95% of the votes cast in favor of the proposal [1][2][3] Company Overview - Sonnet BioTherapeutics Holdings, Inc. is an oncology-focused biotechnology company that utilizes a proprietary platform known as FHAB (Fully Human Albumin Binding) for developing biologic drugs aimed at targeting tumor and lymphatic tissues [6] Business Combination Details - The adjourned special meeting will take place on December 2, 2025, at 9:00 a.m. Eastern Time, with the record date set for October 20, 2025 [4] - The Board of Directors unanimously recommends that stockholders vote in favor of all proposals on the agenda [4] Shareholder Engagement - The company aims to solicit additional votes to meet the required threshold for transaction approval, which necessitates a majority of all outstanding shares [2][3]